In a post from late June of this year, we brought you the story of Amarin Pharmaceuticals – the company arguing for the ability to promote a drug for off-label use. Their case was based on a premise that, at the time, seemed, or so we thought, far-fetched: the FDA, in carrying out its regulatory duties and keeping the public safe from harm, was violating the company’s First Amendment right to free speech.
The company ...
continue reading...